{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:19:45Z","timestamp":1792905585867,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010069.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000}}],"reference-count":32,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010069.pub3","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T14:42:56Z","timestamp":1628692976000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interventions for tophi in gout"],"prefix":"10.1002","volume":"2021","author":[{"given":"Melonie K","family":"Sriranganathan","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine; Changi General Hospital; Singapore City Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ophir","family":"Vinik","sequence":"additional","affiliation":[{"name":"Division of Rheumatology; St Michael's Hospital; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Pardo Pardo","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus; Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[{"name":"Toronto General Research Institute; University Health Network; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; University Hospital Southampton NHS Foundation Trust; Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD010069.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"23","key":"10.1002\/14651858.CD010069.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial","volume":"69","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD010069.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-018-1788-4","article-title":"Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study","volume":"21","author":"Dalbeth","year":"2019","journal-title":"Arthritis Research & Therapy"},{"issue":"1","key":"10.1002\/14651858.CD010069.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment; two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"Journal of the American Medical Association"},{"issue":"10156","key":"10.1002\/14651858.CD010069.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD010069.pub3-BIB0008|cit8","first-page":"e000584","article-title":"Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study","volume":"4","author":"Fleischmann","year":"2018","journal-title":"Rheumatic & Musculoskeletal Diseases Open"},{"issue":"7","key":"10.1002\/14651858.CD010069.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/1060028018762103","article-title":"Lesinurad: a novel agent for management of chronic gout","volume":"52","author":"Haber","year":"2018","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD010069.pub3-BIB0010|cit10","first-page":"812","article-title":"Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-\u03b1 and COX-2","volume":"17","author":"Hao","year":"2019","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"45","key":"10.1002\/14651858.CD010069.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40261-018-0699-0","article-title":"Multicenter, open-label study of long-term topiroxostat (FYX-051) administration in Japanese hyperuricemic patients with or without gout","volume":"38","author":"Hosoya","year":"2018","journal-title":"Clinical Drug Investigation"},{"issue":"9","key":"10.1002\/14651858.CD010069.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/jcph.1119","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of concomitant multiple dose administration of verinurad (RDEA3170) and allopurinol in adult male subjects with gout","volume":"58","author":"Kankam","year":"2018","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","article-title":"Design and rationale for the Veterans Affairs \"Cooperative study program 594 comparative effectiveness in gout: allopurinol vs. febuxostat\" trial","volume":"68","author":"Timilsina","year":"2018","journal-title":"Contemporary Clinical Trials"},{"issue":"13","key":"10.1002\/14651858.CD010069.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0015|cit15","unstructured":"A long-term extension study of lesinurad in combination with allopurinol for subjects completing an efficacy and safety study of lesinurad and allopurinol"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0016|cit16","unstructured":"A study of SEL-212 in patients with gout refractory to conventional therapy (DISSOLVE I)"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0017|cit17","unstructured":"A study of SEL-212 in patients with gout refractory to conventional therapy II (DISSOLVE II)"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0018|cit18","unstructured":"A randomized, double-Blind, placebo-controlled, multicenter, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA\u00ae (Pegloticase) (MIRROR Randomized Controlled Trial (RCT))"},{"issue":"3","key":"10.1002\/14651858.CD010069.pub3-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008335.pub2","article-title":"Pegloticase for chronic gout","author":"Anderson","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0020|cit20","unstructured":"Visual Rx [Computer program]. Version 3; 2008 Available at: www.nntonline.net"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0021|cit21","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0022|cit22","unstructured":"Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD010069.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0024|cit24","unstructured":"GRADEpro GDT McMaster University (developed by EvidencePrime)"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0025|cit25","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"10","key":"10.1002\/14651858.CD010069.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012\u00a0American\u00a0College of Rheumatology guidelines for management of\u00a0gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0027|cit27","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"issue":"11","key":"10.1002\/14651858.CD010069.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2165\/11592290-000000000-00000","article-title":"Difficult-to-treat gouty arthritis: a disease warranting better management","volume":"71","author":"Schlesinger","year":"2011","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0029|cit29","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from\u00a0www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD010069.pub3-BIB0030|cit30","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s).\u00a0Cochrane Handbook for Systematic Reviews of Interventions \u00a0 version 6.1 (updated September 2020). Cochrane, 2020 Available from\u00a0www.training.cochrane.org\/handbook."},{"key":"10.1002\/14651858.CD010069.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Gout","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010069.pub3-BIB0032|cit32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010069.pub2","article-title":"Interventions for tophi in gout","author":"Vinik","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T12:17:34Z","timestamp":1752495454000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010069.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010069.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]}}}